WO2015159263A1 - Pharmaceutical compositions comprising antibacterial agents - Google Patents

Pharmaceutical compositions comprising antibacterial agents Download PDF

Info

Publication number
WO2015159263A1
WO2015159263A1 PCT/IB2015/052812 IB2015052812W WO2015159263A1 WO 2015159263 A1 WO2015159263 A1 WO 2015159263A1 IB 2015052812 W IB2015052812 W IB 2015052812W WO 2015159263 A1 WO2015159263 A1 WO 2015159263A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutically acceptable
acceptable derivative
gram
formula
compound
Prior art date
Application number
PCT/IB2015/052812
Other languages
French (fr)
Inventor
Sachin Bhagwat
Mahesh Vithalbhai Patel
Original Assignee
Wockhardt Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Limited filed Critical Wockhardt Limited
Publication of WO2015159263A1 publication Critical patent/WO2015159263A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • the invention relates to antibacterial compositions and methods for treating or preventing bacterial infections.
  • Bacterial infections continue to remain one of the major causes contributing towards human diseases.
  • One of the key challenges in treatment of bacterial infections is the ability of bacteria to develop resistance to one or more antibacterial agents over time.
  • Examples of such bacteria that have developed resistance to typical antibacterial agents include: Penicillin-resistant Streptococcus pneumoniae, Vancomycin-resistant Enterococci, and Methicillin-resistant Staphylococcus aureus.
  • Penicillin-resistant Streptococcus pneumoniae Vancomycin-resistant Enterococci
  • Methicillin-resistant Staphylococcus aureus The problem of emerging drug-resistance in bacteria is often tackled by switching to newer antibacterial agents, which can be more expensive and sometimes more toxic. Additionally, this may not be a permanent solution as the bacteria often develop resistance to the newer antibacterial agents as well in due course.
  • bacteria are particularly efficient in developing resistance, because of their ability to multiply very rapidly and pass on the resistance genes as they replicate.
  • beta-lactam antibacterial agents The persistent exposure of bacterial strains to a multitude of beta-lactam antibacterial agents has led to overproduction and mutation of beta-lactamases.
  • ESBL extended spectrum beta-lactamases
  • ESBL beta-lactamases
  • compositions comprising aztreonam and certain nitrogen containing bicyclic compounds exhibit unexpectedly synergistic antibacterial activity, even against highly resistant bacterial strains.
  • compositions comprising: (a) aztreonam or a pharmaceutically acceptable derivative thereof, and (b) a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof:
  • compositions comprising: (a) aztreonam or a pharmaceutically acceptable derivative thereof, and (b) a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof; wherein a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof is present in the composition in an amount from about 0.01 gram to about 8 gram per gram of aztreonam or a pharmaceutically acceptable derivative thereof.
  • methods for treating or preventing a bacterial infection in a subject comprising administering to said subject an effective amount of a pharmaceutical composition comprising: (a) aztreonam or a pharmaceutically acceptable derivative thereof; and (b) a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof.
  • methods for treating or preventing a bacterial infection in a subject comprising administering to said subject an effective amount of a pharmaceutical composition comprising: (a) aztreonam or a pharmaceutically acceptable derivative thereof, and (b) a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof; wherein a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof is present in the composition in an amount from about 0.01 gram to about 8 gram per gram of aztreonam or a pharmaceutically acceptable derivative thereof.
  • methods for treating or preventing a bacterial infection in a subject comprising administering to said subject an effective amount of: (a) aztreonam or a pharmaceutically acceptable derivative thereof; and (b) a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof.
  • methods for treating or preventing a bacterial infection in a subject comprising administering to said subject an effective amount of: (a) aztreonam or a pharmaceutically acceptable derivative thereof, and (b) a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof; wherein a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof is administered in an amount from about 0.01 gram to about 8 gram per gram of aztreonam or a pharmaceutically acceptable derivative thereof.
  • a pharmaceutical composition comprising: (a) aztreonam or a pharmaceutically acceptable derivative thereof, and (b) a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof exhibits unexpectedly improved antibacterial efficacy, even against highly resistant bacteria, including those producing extended spectrum beta-lactamase enzymes (ESBLs).
  • ESBLs extended spectrum beta-lactamase enzymes
  • infection or "bacterial infection” as used herein includes presence of bacteria, in or on a subject, which, if its growth were inhibited, would result in a benefit to the subject.
  • infection in addition to referring to the presence of bacteria also refers to presence of other floras, which are not desirable.
  • infection includes infection caused by bacteria.
  • treat refers to administration of a medicament, including a pharmaceutical composition, or one or more pharmaceutically active ingredients, for prophylactic and/or therapeutic purposes.
  • prophylactic treatment refers to treating a subject who is not yet infected, but who is susceptible to, or otherwise at a risk of infection (preventing the bacterial infection).
  • therapeutic treatment refers to administering treatment to a subject already suffering from infection.
  • treat also refer to administering compositions, or one or more of pharmaceutically active ingredients discussed herein, with or without additional pharmaceutically active or inert ingredients, in order to: (i) reduce or eliminate either a bacterial infection, or one or more symptoms of a bacterial infection, or (ii) retard progression of a bacterial infection, or one or more symptoms of a bacterial infection, or (iii) reduce severity of a bacterial infection, or one or more symptoms of a bacterial infection, or (iv) suppress clinical manifestation of a bacterial infection, or (v) suppress manifestation of adverse symptoms of a bacterial infection.
  • a “therapeutically effective amount” or “pharmaceutically effective amount” or “effective amount” as used herein refer to an amount, which has a therapeutic effect or is the amount required to produce a therapeutic effect in a subject.
  • a “therapeutically effective amount” or “pharmaceutically effective amount” or “effective amount” of an antibacterial agent or a pharmaceutical composition is the amount of the antibacterial agent or the pharmaceutical composition required to produce a desired therapeutic effect as may be judged by clinical trial results, model animal infection studies, and/or in vitro studies (e.g. in agar or broth media).
  • Such effective amount depends on several factors, including but not limited to, the microorganism (e.g.
  • a prophylactic ally effective amount is that amount which would be effective in preventing the bacterial infection.
  • administration refers to and includes delivery of a composition, or one or more pharmaceutically active ingredients to a subject, including for example, by any appropriate method, which serves to deliver the composition or its active ingredients or other pharmaceutically active ingredients to the site of infection.
  • the method of administration may vary depending on various factors, such as for example, the components of the pharmaceutical composition or type/nature of the pharmaceutically active or inert ingredients, site of the potential or actual infection, the microorganism involved, severity of the infection, age and physical condition of the subject and a like.
  • Some non-limiting examples of ways to administer a composition or a pharmaceutically active ingredient to a subject according to this invention include oral, intravenous, topical, intrarespiratory, intraperitoneal, intramuscular, parenteral, sublingual, transdermal, intranasal, aerosol, intraocular, intratracheal, intrarectal, vaginal, gene gun, dermal patch, eye drop and mouthwash.
  • a pharmaceutical composition comprising more than one ingredients (active or inert)
  • one of the ways of administering such composition is by admixing the ingredients (e.g. in the form of a suitable unit dosage form such as tablet, capsule, solution, powder or a like) and then administering the dosage form.
  • the ingredients may also be administered separately (simultaneously or one after the other) as long as these ingredients reach beneficial therapeutic levels such that the composition as a whole provides a synergistic and/or desired effect.
  • growth refers to a growth of one or more microorganisms and includes reproduction or population expansion of the microorganism (e.g. bacteria).
  • growth also includes maintenance of on-going metabolic processes of the microorganism, including the processes that keep the microorganism alive.
  • an antibacterial effectiveness refers to the ability of the composition or the antibacterial agent to prevent or treat bacterial infection in a subject.
  • antibacterial agent refers to any substance, compound, a combination of substances, or a combination of compounds capable of: (i) inhibiting, reducing or preventing growth of bacteria; (ii) inhibiting or reducing ability of a bacteria to produce infection in a subject; or (iii) inhibiting or reducing ability of bacteria to multiply or remain infective in the environment.
  • antibacterial agent also refers to compounds capable of decreasing infectivity or virulence of bacteria.
  • beta-lactam antibacterial agent refers to compounds with antibacterial properties and containing a beta-lactam nucleus in their molecular structure.
  • beta-lactamase or "beta-lactamase enzyme” as used herein refers to any enzyme or protein or any other substance that breaks down a beta-lactam ring.
  • beta- lactamase includes enzymes that are produced by bacteria and have the ability to hydrolyse the beta-lactam ring in a beta-lactam compound, either partially or completely.
  • extended spectrum beta-lactamase includes those beta- lactamase enzymes, which are capable of conferring bacterial resistance to various beta-lactam antibacterial agents such as penicillins, cephalosporins, aztreonam and the like.
  • beta-lactamase inhibitor refers to a compound capable of inhibiting activity of one or more beta-lactamase enzymes, either partially or completely.
  • colony forming units or "CFU” as used herein refers to an estimate of number of viable bacterial cells per ml of the sample. Typically, a “colony of bacteria” refers to a mass of individual bacteria growing together.
  • pharmaceutically inert ingredient or “carrier” or “excipient” refers to and includes compounds or materials used to facilitate administration of a compound, for example, to increase the solubility of the compound.
  • solid carriers include starch, lactose, dicalcium phosphate, sucrose, and kaolin.
  • Typical, non-limiting examples of liquid carriers include sterile water, saline, buffers, non-ionic surfactants, and edible oils.
  • various adjuvants commonly used in the art may also be included. These and other such compounds are described in literature, e.g., in the Merck Index (Merck & Company, Rahway, N.J.).
  • subject refers to vertebrate or invertebrate, including a mammal.
  • subject includes human, animal, a bird, a fish, or an amphibian. Typical, non-limiting examples of a “subject” include humans, cats, dogs, horses, sheep, bovine cows, pigs, lambs, rats, mice and guinea pigs.
  • pharmaceutically acceptable derivative refers to and includes any pharmaceutically acceptable salt, pro-drug, metabolite, ester, ether, hydrate, polymorph, solvate, complex, and adduct of a compound described herein which, upon administration to a subject, is capable of providing (directly or indirectly) the parent compound.
  • pharmaceutically acceptable salt refers to one or more salts of a given compound which possesses desired pharmacological activity of the free compound and which is neither biologically nor otherwise undesirable.
  • pharmaceutically acceptable salts refer to salts that are suitable for use in contact with the tissues of human and animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
  • Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge, et al. ( . Pharmaceutical Sciences, 66; 1-19, 1977), incorporated herein by reference in its entirety, describes various pharmaceutically acceptable salts in details.
  • stereoisomer refers to and includes isomeric molecules that have the same molecular formula but differ in positioning of atoms and/or functional groups in the space. Stereoisomers may further be classified as enantiomers (where different isomers are mirror- images of each other) and diastereomers (where different isomers are not mirror-images of each other). Diastereomers include isomers such as conformers, meso compounds, cis-trans (E-Z) isomers, and non-enantiomeric optical isomers.
  • compositions comprising: (a) aztreonam or a pharmaceutically acceptable derivative thereof, and (b) a compound of Formula (I) or a stereoisomer or a pharmaceuticall acceptable derivative thereof:
  • Compound of Formula (I), according to the invention can be used in various forms including as such, a stereoisomer or a pharmaceutically acceptable derivative thereof.
  • a compound of Formula (I) (CAS Registry Number: 1463521-39-2) may also be known chemically by different names including the following: (a) "irans-sulfuric acid mono- ⁇ 2-[5-(3-aminopropyl)- [l,3,4]oxadiazol-2-yl]-7-oxo-l ,6-diaza-bicyclo[3.2.1]oct-6-yl ⁇ ester" (b) "(25,5R)-2-(5-(3- aminopropyl)-l ,3,4-oxadiazol-2-yl-7-oxo-l ,6-diazabicyclo[3.2.1]octan-6-yl hydrogen sulphate"; (c) "ir ns-6-(sulphooxy)-2-(5-(3-aminopropy
  • Compound of Formula (I) may also be used in the form of its stereoisomer or a pharmaceutically acceptable derivative thereof.
  • suitable pharmaceutically acceptable derivatives of a compound of Formula (I) include its sodium salt and potassium salt.
  • compositions comprising: (a) aztreonam or a pharmaceutically acceptable derivative thereof, and (b) a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof; wherein a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof is present in the composition in an amount from about 0.01 gram to about 8 gram per gram of aztreonam or a pharmaceutically acceptable derivative thereof.
  • Both, aztreonam and a compound of Formula (I) may be present in the composition in their free forms or in the form of their pharmaceutically acceptable derivatives (such as salts, pro-drugs, metabolites, esters, ethers, hydrates, polymorphs, solvates, complexes, or adducts).
  • the specified ratio of aztreonam and compound of Formula (I) in the composition is calculated on the basis of their free forms. For example, if the composition comprises sodium salt of compound of Formula (I), the ratio of aztreonam to compound of Formula (I) is calculated using the equivalent amount of compound of Formula (I) present in the composition.
  • a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and aztreonam or a pharmaceutically acceptable derivative thereof in the composition may vary depending on clinical requirements.
  • a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof in the composition is present in an amount from about 0.01 gram to about 10 gram.
  • aztreonam or a pharmaceutically acceptable derivative thereof in the composition is present in an amount from about 0.01 gram to about 10 gram.
  • the pharmaceutical composition according to the invention comprises about 0.25 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 0.5 gram of aztreonam or a pharmaceutically acceptable derivative thereof. In some other embodiments, the pharmaceutical composition according to the invention comprises about 0.5 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 0.5 gram of aztreonam or a pharmaceutically acceptable derivative thereof.
  • the pharmaceutical composition according to the invention comprises about 1 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 0.5 gram of aztreonam or a pharmaceutically acceptable derivative thereof.
  • the pharmaceutical composition according to the invention comprises about 2 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 0.5 gram of aztreonam or a pharmaceutically acceptable derivative thereof.
  • the pharmaceutical composition according to the invention comprises about 0.25 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 1 gram of aztreonam or a pharmaceutically acceptable derivative thereof.
  • the pharmaceutical composition according to the invention comprises about 1 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 1 gram of aztreonam or a pharmaceutically acceptable derivative thereof.
  • the pharmaceutical composition according to the invention comprises about 2 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 1 gram of aztreonam or a pharmaceutically acceptable derivative thereof.
  • the pharmaceutical composition according to the invention comprises about 4 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 1 gram of aztreonam or a pharmaceutically acceptable derivative thereof.
  • the pharmaceutical composition according to the invention comprises about 2 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 2 gram of aztreonam or a pharmaceutically acceptable derivative thereof.
  • the pharmaceutical composition according to the invention comprises about 1 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 2 gram of aztreonam or a pharmaceutically acceptable derivative thereof.
  • compositions according to the invention may include one or more pharmaceutically acceptable carriers or excipients or the like.
  • Typical, non-limiting examples of such carriers or excipients include mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, sodium crosscarmellose, glucose, gelatine, sucrose, magnesium carbonate, wetting agents, emulsifying agents, solubilizing agents, buffering agents, lubricants, preservatives, stabilizing agents, binding agents and the like.
  • the compositions according to present invention comprise arginine or a pharmaceutically acceptable salt thereof.
  • the amount of arginine or a pharmaceutically acceptable salt thereof in the composition can vary widely depending on the requirement.
  • arginine or a pharmaceutically acceptable salt thereof is present in the composition in an amount of about 0.01 gram to about 5 gram of arginine or a pharmaceutically acceptable salt thereof per gram of aztreonam or a pharmaceutically acceptable salt thereof. In some other embodiments, arginine or a pharmaceutically acceptable salt thereof is present in the composition in an amount of about 0.01 gram to about 1 gram of arginine or a pharmaceutically acceptable salt thereof per gram of aztreonam or a pharmaceutically acceptable salt thereof.
  • compositions or the active ingredients according to the present invention may be formulated into a variety of dosage forms, such as solid, semi-solid, liquid and aerosol dosage forms.
  • dosage forms such as solid, semi-solid, liquid and aerosol dosage forms.
  • Typical, non-limiting examples of some dosage forms include tablets, capsules, powders, solutions, suspensions, suppositories, aerosols, granules, emulsions, syrups, elixirs and the like.
  • compositions according to the invention are in the form of a powder or a solution. In some other embodiments, pharmaceutical compositions according to the invention are present in the form of a powder or a solution that can be reconstituted by addition of a compatible reconstitution diluent prior to administration. In some other embodiments, pharmaceutical compositions according to the invention are in the form of a frozen composition that can be diluted with a compatible reconstitution diluent prior to administration. Typical, non-limiting example of suitable compatible reconstitution diluent includes water.
  • compositions according to the invention are present in the form ready to use for parenteral administration.
  • compositions according to the invention can be formulated into various dosage forms wherein the active ingredients and/or excipients may be present either together (e.g. as an admixture) or as separate components.
  • the various ingredients in the composition are formulated as a mixture, such compositions can be delivered by administering such a mixture to a subject using any suitable route of administration.
  • pharmaceutical compositions according to the invention may also be formulated into a dosage form wherein one or more ingredients (such as active or inactive ingredients) are present as separate components.
  • the composition or dosage form wherein the ingredients do not come as a mixture, but come as separate components, such composition/dosage form may be administered in several ways.
  • the ingredients may be mixed in the desired proportions and the mixture is reconstituted in suitable reconstitution diluent and is then administered as required.
  • the components or the ingredients may be separately administered (simultaneously or one after the other) in appropriate proportion so as to achieve the same or equivalent therapeutic level or effect as would have been achieved by administration of the equivalent mixture.
  • compositions according to the invention are used in treatment or prevention of a bacterial infection.
  • a pharmaceutical composition comprising administering to said subject effective amount of a pharmaceutical composition according to the invention.
  • a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and aztreonam or a pharmaceutically acceptable derivative thereof are present in the composition as separate components; a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof may be administered before, after or simultaneously with the administration of aztreonam or a pharmaceutically acceptable derivative thereof.
  • methods for treating or preventing bacterial infections in a subject comprising administering to said subject an effective amount of: (a) aztreonam or a pharmaceutically acceptable derivative thereof, and (b) a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof: H 2 N
  • methods for treating or preventing bacterial infections in a subject comprising administering to said subject an effective amount of: (a) aztreonam or a pharmaceutically acceptable derivative thereof, and (b) a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof; wherein amount of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof administered is from about 0.01 gram to about 8 gram per gram of aztreonam or a pharmaceutically acceptable derivative thereof.
  • a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof is administered in an amount from about 0.01 gram to about 10 gram. In some other embodiments, in the methods according to the invention, aztreonam or a pharmaceutically acceptable derivative thereof is administered in an amount from about 0.01 gram to about 10 gram.
  • compositions or one or more active ingredients according to the invention are administered parenterally or orally.
  • a compound of Formula (I) is "irans-sulfuric acid mono- ⁇ 2-[5-(3-aminopropyl)-[l,3,4]oxadiazol-2- yl]-7-oxo-l,6-diaza-bicyclo[3.2.1]oct-6-yl ⁇ ester"; "(25,5i?)-2-(5-(3-aminopropyl)-l ,3,4- oxadiazol-2-yl-7-oxo-l ,6-diazabicyclo[3.2.1]octan-6-yl hydrogen sulphate"; "trans-6- (sulphooxy)-2-(5-(3-aminopropyl)-[l,3,4]-oxadiazol-2-yl)-7-oxo-l,6-diazabicyclo [3.2.1]-octane” or "sulfuric acid, mono [
  • compositions and methods according to the invention a compound of Formula (I) a stereoisomer thereof is present as a sodium or potassium salt.
  • compositions and methods comprising sodium or potassium salt of sulfuric acid, mono [(li?,25,5i?)-2-[5-(3-aminopropyl)-l ,3,4-oxadiazol-2-yl]-7-oxo-l,6-diazabicyclo[3.2.1]oct-6- yljester or a stereoisomer thereof.
  • a method for increasing antibacterial effectiveness of aztreonam or a pharmaceutically acceptable derivative thereof in a subject comprising co-administering aztreonam or a pharmaceutically acceptable derivative thereof, with a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, wherein the amount of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof is from about 0.01 gram to about 8 gram per gram of aztreonam or a pharmaceutically acceptable derivative thereof.
  • bacterial infections can be treated or prevented using compositions and methods according to the invention.
  • Typical, non -limiting examples of bacterial infections that can be treated or prevented using methods and/or pharmaceutical compositions according to the invention include E. coli infections, Yersinia pestis (pneumonic plague), staphylococcal infection, mycobacteria infection, bacterial pneumonia, Shigella dysentery, Serratia infections, Candida infections, Cryptococcal infection, anthrax, tuberculosis or infections caused by Pseudomonas aeruginosa, Acinetobacter baumannii or methicillin resistant Staphylococcus aurues (MRSA) etc.
  • E. coli infections E. coli infections, Yersinia pestis (pneumonic plague), staphylococcal infection, mycobacteria infection, bacterial pneumonia, Shigella dysentery, Serratia infections, Candida infections, Cryptococcal infection, anthrax, tuberculosis or infections caused by Pseudomon
  • compositions and methods according to the invention are useful in treatment or prevention of several infections, including for example, skin and soft tissue infections, febrile neutropenia, urinary tract infection, intraabdominal infections, respiratory tract infections, pneumonia (nosocomial), bacteremia meningitis, surgical infections and the like.
  • compositions and methods according to the invention are used in treatment or prevention of infections caused by resistant bacteria. In some other embodiments, the compositions and methods according to the invention are used in treatment or prevention of infections caused by bacteria producing one or more beta-lactamase enzymes.
  • compositions and methods disclosed herein are also effective in preventing or treating infections caused by bacteria that are considered to be less or not susceptible to one or more of known antibacterial agents or their known compositions.
  • bacteria known to have developed resistance to various antibacterial agents include Acinetobacter, Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, Enterobacter, Klebsiella, Citrobacter and a like.
  • a method for preventing or treating a bacterial infection in a subject comprising administering to said subject: (a) aztreonam or a pharmaceutically acceptable derivative thereof, and (b) compound of Formula (I) or stereoisomer or a pharmaceutically acceptable derivative thereof.
  • the synergistic killing effect of the combinations according to invention was studied by performing time kill studies.
  • the freshly grown cultures were diluted to the required cell density (initial starting inoculum) in Cation adjusted Muller Hinton broth medium (BD, USA).
  • the antibacterial agents either alone or in combination
  • the samples were incubated under shaking condition (120 rpm) at 37°C. Enumeration of viable bacterial count was done every 2 hour by diluting in normal saline and plating on to the Tryptic Soya Agar plates (BD, USA). The plates were incubated for 24 hours to arrive at the viable bacterial count.
  • Tables 1 and 2 The results of these studies are summarized in Tables 1 and 2, wherein the antibacterial activity is expressed in terms of Logio CFU (Colony Forming Units) per ml. In general, the decrease of 1 Logio CFU/ml, corresponds to 90% killing of bacteria. Similarly, 2 Logio CFU/ml reductions indicates to 99% killing of bacteria and 3 Log CFU/ml reductions is equal to 99.9% killing of bacteria.
  • Table 1 details the antibacterial activity of the combination according to invention against highly resistant K. pneumoniae NCTC 13443 strain producing NDM-1 , CMY Type, DHA-1/2, SHV, TEM beta-lactamase enzymes. The assay without any antibacterial agent was taken as control.
  • Table 2 details the antibacterial activity of the combination according to invention against highly resistant K. pneumoniae B88 strain producing NDM-1 , SHV, TEM and CTX-M Grl beta- lactamase enzymes.
  • the assay without any antibacterial agent was taken as control.
  • aztreonam (at 4 mcg/ml), imipenem (at 4 mcg/ml) and a compound of Formula (I) (at 4 mcg/ml) when used alone were not effective in decreasing the bacterial count of K. pneumoniae B88 throughout the duration of the study.
  • the combination of aztreonam and a compound of Formula (I) exhibited synergistic killing of the resistant strains of K. pneumonia B88.
  • the data reveals that combination of aztreonam (at 4 mcg/ml) and a compound of Formula (I) (at 4 mcg/ml) significantly reduced bacterial count over longer duration of times.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Pharmaceutical compositions comprising aztreonam or a pharmaceutically acceptable derivative, and a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof are disclosed.

Description

PHARMACEUTICAL COMPOSITIONS COMPRISING ANTIBACTERIAL AGENTS
RELATED PATENT APPLICATIONS
This application claims priority to Indian Patent Application No. 1409/MUM/2014 filed on April 18, 2014 the disclosures of which are incorporated herein by reference in its entirety as if fully rewritten herein.
FIELD OF THE INVENTION
The invention relates to antibacterial compositions and methods for treating or preventing bacterial infections.
BACKGROUND OF THE INVENTION
Bacterial infections continue to remain one of the major causes contributing towards human diseases. One of the key challenges in treatment of bacterial infections is the ability of bacteria to develop resistance to one or more antibacterial agents over time. Examples of such bacteria that have developed resistance to typical antibacterial agents include: Penicillin-resistant Streptococcus pneumoniae, Vancomycin-resistant Enterococci, and Methicillin-resistant Staphylococcus aureus. The problem of emerging drug-resistance in bacteria is often tackled by switching to newer antibacterial agents, which can be more expensive and sometimes more toxic. Additionally, this may not be a permanent solution as the bacteria often develop resistance to the newer antibacterial agents as well in due course. In general, bacteria are particularly efficient in developing resistance, because of their ability to multiply very rapidly and pass on the resistance genes as they replicate.
The persistent exposure of bacterial strains to a multitude of beta-lactam antibacterial agents has led to overproduction and mutation of beta-lactamases. These new extended spectrum beta-lactamases (ESBL) are capable of hydro lyzing penicillins, cephalosporins, monobactams and even carbapenems. Such a wide spread resistance to many of the existing beta-lactam antibacterial agents, either used alone or in combination with other agents, is posing challenges in treating serious bacterial infections.
Therefore, there is a need for development of newer ways to treat infections that are becoming resistant to known therapies and methods. Surprisingly, it has been found that a compositions comprising aztreonam and certain nitrogen containing bicyclic compounds exhibit unexpectedly synergistic antibacterial activity, even against highly resistant bacterial strains.
SUMMARY OF THE INVENTION
Accordingly, there are provided pharmaceutical compositions comprising: (a) aztreonam or a pharmaceutically acceptable derivative thereof, and (b) a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof:
Figure imgf000003_0001
Formula (I)
In one general aspect, there are provided pharmaceutical compositions comprising: (a) aztreonam or a pharmaceutically acceptable derivative thereof, and (b) a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof; wherein a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof is present in the composition in an amount from about 0.01 gram to about 8 gram per gram of aztreonam or a pharmaceutically acceptable derivative thereof.
In yet another general aspect, there are provided methods for treating or preventing a bacterial infection in a subject, said methods comprising administering to said subject an effective amount of a pharmaceutical composition comprising: (a) aztreonam or a pharmaceutically acceptable derivative thereof; and (b) a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof.
In another general aspect, there are provided methods for treating or preventing a bacterial infection in a subject, said methods comprising administering to said subject an effective amount of a pharmaceutical composition comprising: (a) aztreonam or a pharmaceutically acceptable derivative thereof, and (b) a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof; wherein a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof is present in the composition in an amount from about 0.01 gram to about 8 gram per gram of aztreonam or a pharmaceutically acceptable derivative thereof.
In yet another general aspect, there are provided methods for treating or preventing a bacterial infection in a subject, said methods comprising administering to said subject an effective amount of: (a) aztreonam or a pharmaceutically acceptable derivative thereof; and (b) a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof.
In another general aspect, there are provided methods for treating or preventing a bacterial infection in a subject, said methods comprising administering to said subject an effective amount of: (a) aztreonam or a pharmaceutically acceptable derivative thereof, and (b) a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof; wherein a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof is administered in an amount from about 0.01 gram to about 8 gram per gram of aztreonam or a pharmaceutically acceptable derivative thereof.
The details of one or more embodiments of the invention are set forth in the description below. Other features, objects and advantages of the invention will be apparent from the following description including claims. DETAILED DESCRIPTION OF THE INVENTION
Reference will now be made to the exemplary embodiments, and specific language will be used herein to describe the same. It should nevertheless be understood that no limitation of the scope of the invention is thereby intended. Alterations and further modifications of the inventive features illustrated herein, which would occur to one skilled in the relevant art and having possession of this disclosure, are to be considered within the scope of the invention. It must be noted that, as used in this specification and the appended claims, the singular forms "a", "an", and "the" include plural referents unless the content clearly dictates otherwise. All references including patents, patent applications, and literature cited in the specification are expressly incorporated herein by reference in their entirety as if fully rewritten herein.
The inventors have surprisingly discovered that a pharmaceutical composition comprising: (a) aztreonam or a pharmaceutically acceptable derivative thereof, and (b) a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof exhibits unexpectedly improved antibacterial efficacy, even against highly resistant bacteria, including those producing extended spectrum beta-lactamase enzymes (ESBLs).
The term "infection" or "bacterial infection" as used herein includes presence of bacteria, in or on a subject, which, if its growth were inhibited, would result in a benefit to the subject. As such, the term "infection" in addition to referring to the presence of bacteria also refers to presence of other floras, which are not desirable. The term "infection" includes infection caused by bacteria.
The term "treat", "treating" or "treatment" as used herein refers to administration of a medicament, including a pharmaceutical composition, or one or more pharmaceutically active ingredients, for prophylactic and/or therapeutic purposes. The term "prophylactic treatment" refers to treating a subject who is not yet infected, but who is susceptible to, or otherwise at a risk of infection (preventing the bacterial infection). The term "therapeutic treatment" refers to administering treatment to a subject already suffering from infection. The terms "treat", "treating" or "treatment" as used herein also refer to administering compositions, or one or more of pharmaceutically active ingredients discussed herein, with or without additional pharmaceutically active or inert ingredients, in order to: (i) reduce or eliminate either a bacterial infection, or one or more symptoms of a bacterial infection, or (ii) retard progression of a bacterial infection, or one or more symptoms of a bacterial infection, or (iii) reduce severity of a bacterial infection, or one or more symptoms of a bacterial infection, or (iv) suppress clinical manifestation of a bacterial infection, or (v) suppress manifestation of adverse symptoms of a bacterial infection.
The terms "pharmaceutically effective amount" or "therapeutically effective amount" or "effective amount" as used herein refer to an amount, which has a therapeutic effect or is the amount required to produce a therapeutic effect in a subject. For example, a "therapeutically effective amount" or "pharmaceutically effective amount" or "effective amount" of an antibacterial agent or a pharmaceutical composition is the amount of the antibacterial agent or the pharmaceutical composition required to produce a desired therapeutic effect as may be judged by clinical trial results, model animal infection studies, and/or in vitro studies (e.g. in agar or broth media). Such effective amount depends on several factors, including but not limited to, the microorganism (e.g. bacteria) involved, characteristics of the subject (for example height, weight, sex, age and medical history), severity of infection and particular type of the antibacterial agent used. For prophylactic treatments, a prophylactic ally effective amount is that amount which would be effective in preventing the bacterial infection.
The term "administration" or "administering" refers to and includes delivery of a composition, or one or more pharmaceutically active ingredients to a subject, including for example, by any appropriate method, which serves to deliver the composition or its active ingredients or other pharmaceutically active ingredients to the site of infection. The method of administration may vary depending on various factors, such as for example, the components of the pharmaceutical composition or type/nature of the pharmaceutically active or inert ingredients, site of the potential or actual infection, the microorganism involved, severity of the infection, age and physical condition of the subject and a like. Some non-limiting examples of ways to administer a composition or a pharmaceutically active ingredient to a subject according to this invention include oral, intravenous, topical, intrarespiratory, intraperitoneal, intramuscular, parenteral, sublingual, transdermal, intranasal, aerosol, intraocular, intratracheal, intrarectal, vaginal, gene gun, dermal patch, eye drop and mouthwash. In case of a pharmaceutical composition comprising more than one ingredients (active or inert), one of the ways of administering such composition is by admixing the ingredients (e.g. in the form of a suitable unit dosage form such as tablet, capsule, solution, powder or a like) and then administering the dosage form. Alternatively, the ingredients may also be administered separately (simultaneously or one after the other) as long as these ingredients reach beneficial therapeutic levels such that the composition as a whole provides a synergistic and/or desired effect.
The term "growth" as used herein refers to a growth of one or more microorganisms and includes reproduction or population expansion of the microorganism (e.g. bacteria). The term "growth" also includes maintenance of on-going metabolic processes of the microorganism, including the processes that keep the microorganism alive.
The term, "effectiveness" as used herein refers to ability of a treatment, or a composition, or one or more pharmaceutically active ingredients to produce a desired biological effect in a subject. For example, the term "antibacterial effectiveness" of a composition or of an antibacterial agent refers to the ability of the composition or the antibacterial agent to prevent or treat bacterial infection in a subject.
The term "synergistic" or "synergy" as used herein refers to the interaction of two or more agents so that their combined effect is greater than their individual effects.
The term "antibacterial agent" as used herein refers to any substance, compound, a combination of substances, or a combination of compounds capable of: (i) inhibiting, reducing or preventing growth of bacteria; (ii) inhibiting or reducing ability of a bacteria to produce infection in a subject; or (iii) inhibiting or reducing ability of bacteria to multiply or remain infective in the environment. The term "antibacterial agent" also refers to compounds capable of decreasing infectivity or virulence of bacteria.
The term "beta-lactam antibacterial agent" as used herein refers to compounds with antibacterial properties and containing a beta-lactam nucleus in their molecular structure.
The term "beta-lactamase" or "beta-lactamase enzyme" as used herein refers to any enzyme or protein or any other substance that breaks down a beta-lactam ring. The term "beta- lactamase" includes enzymes that are produced by bacteria and have the ability to hydrolyse the beta-lactam ring in a beta-lactam compound, either partially or completely.
The term "extended spectrum beta-lactamase" (ESBL) as used herein includes those beta- lactamase enzymes, which are capable of conferring bacterial resistance to various beta-lactam antibacterial agents such as penicillins, cephalosporins, aztreonam and the like.
The term "beta-lactamase inhibitor" as used herein refers to a compound capable of inhibiting activity of one or more beta-lactamase enzymes, either partially or completely.
The term "colony forming units" or "CFU" as used herein refers to an estimate of number of viable bacterial cells per ml of the sample. Typically, a "colony of bacteria" refers to a mass of individual bacteria growing together.
The term "pharmaceutically inert ingredient" or "carrier" or "excipient" refers to and includes compounds or materials used to facilitate administration of a compound, for example, to increase the solubility of the compound. Typical, non-limiting examples of solid carriers include starch, lactose, dicalcium phosphate, sucrose, and kaolin. Typical, non-limiting examples of liquid carriers include sterile water, saline, buffers, non-ionic surfactants, and edible oils. In addition, various adjuvants commonly used in the art may also be included. These and other such compounds are described in literature, e.g., in the Merck Index (Merck & Company, Rahway, N.J.). Considerations for inclusion of various components in pharmaceutical compositions are described, e.g., in Gilman et al. (Goodman and Gilman's: The Pharmacological Basis of Therapeutics, 8th Ed., Pergamon Press., 1990), which is incorporated herein by reference in its entirety.
The term "subject" as used herein refers to vertebrate or invertebrate, including a mammal. The term "subject" includes human, animal, a bird, a fish, or an amphibian. Typical, non-limiting examples of a "subject" include humans, cats, dogs, horses, sheep, bovine cows, pigs, lambs, rats, mice and guinea pigs. The term "pharmaceutically acceptable derivative" as used herein refers to and includes any pharmaceutically acceptable salt, pro-drug, metabolite, ester, ether, hydrate, polymorph, solvate, complex, and adduct of a compound described herein which, upon administration to a subject, is capable of providing (directly or indirectly) the parent compound. For example, the term "antibacterial agent or a pharmaceutically acceptable derivative thereof includes all derivatives of the antibacterial agent (such as salts, pro-drugs, metabolites, esters, ethers, hydrates, polymorphs, solvates, complexes, and adducts) which, upon administration to a subject, are capable of providing (directly or indirectly) the antibacterial agent.
The term "pharmaceutically acceptable salt" as used herein refers to one or more salts of a given compound which possesses desired pharmacological activity of the free compound and which is neither biologically nor otherwise undesirable. In general, the term "pharmaceutically acceptable salts" refer to salts that are suitable for use in contact with the tissues of human and animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge, et al. ( . Pharmaceutical Sciences, 66; 1-19, 1977), incorporated herein by reference in its entirety, describes various pharmaceutically acceptable salts in details.
A reference to aztreonam is intended to include its pharmaceutically acceptable salts, prodrugs, metabolites, esters, ethers, hydrates, polymorphs, solvates, complexes, enantiomers, adducts and its any other pharmaceutically acceptable derivative.
The term "stereoisomer" as used herein refers to and includes isomeric molecules that have the same molecular formula but differ in positioning of atoms and/or functional groups in the space. Stereoisomers may further be classified as enantiomers (where different isomers are mirror- images of each other) and diastereomers (where different isomers are not mirror-images of each other). Diastereomers include isomers such as conformers, meso compounds, cis-trans (E-Z) isomers, and non-enantiomeric optical isomers.
A person of skills in the art would appreciate that various compounds described herein (including, for example a compound of Formula (I) and aztreonam) can exist and are often used as their pharmaceutically acceptable derivatives (such as salts, pro-drugs, metabolites, esters, ethers, hydrates, polymorphs, solvates, complexes, and adducts).
In one general aspect, there are provided pharmaceutical compositions comprising: (a) aztreonam or a pharmaceutically acceptable derivative thereof, and (b) a compound of Formula (I) or a stereoisomer or a pharmaceuticall acceptable derivative thereof:
Figure imgf000010_0001
Formula (I)
Compound of Formula (I), according to the invention can be used in various forms including as such, a stereoisomer or a pharmaceutically acceptable derivative thereof. A compound of Formula (I) (CAS Registry Number: 1463521-39-2) may also be known chemically by different names including the following: (a) "irans-sulfuric acid mono-{2-[5-(3-aminopropyl)- [l,3,4]oxadiazol-2-yl]-7-oxo-l ,6-diaza-bicyclo[3.2.1]oct-6-yl} ester" (b) "(25,5R)-2-(5-(3- aminopropyl)-l ,3,4-oxadiazol-2-yl-7-oxo-l ,6-diazabicyclo[3.2.1]octan-6-yl hydrogen sulphate"; (c) "ir ns-6-(sulphooxy)-2-(5-(3-aminopropyl)-[l,3,4]-oxadiazol-2-yl)-7-oxo-l,6-diazabicyclo [3.2.1]-octane" or (d) "sulfuric acid, mono [(li?,25,5i?)-2-[5-(3-aminopropyl)-l,3,4-oxadiazol-2- yl]-7-oxo-l,6-diazabicyclo[3.2.1]oct-6-yl]ester. A reference to "a compound of Formula (I)" is intended to include compounds chemically known as: (a) "as irans-sulfuric acid mono-{2-[5-(3- aminopropyl)-[l,3,4]oxadiazol-2-yl]-7-oxo-l,6-diazabicyclo[3.2.1]oct-6-yl} ester" (b) "(25,5i?)-2- (5-(3-aminopropyl)-l ,3,4-oxadiazol-2-yl-7-oxo-l ,6-diazabicyclo [3.2.1]octan-6-yl hydrogen sulphate"; (c) "ir ns-6-(sulphooxy)-2-(5-(3-aminopropyl)-[l,3,4]-oxadiazol-2-yl)-7-oxo-l ,6- diazabicyclo[3.2.1]-octane" and (d) "sulfuric acid, mono [(li?,25,5i?)-2-[5-(3-aminopropyl)-l ,3,4- oxadiazol-2-yl]-7-oxo-l,6-diazabicyclo[3.2.1]oct-6-yl]ester.
Compound of Formula (I) may also be used in the form of its stereoisomer or a pharmaceutically acceptable derivative thereof. Typical, non-limiting examples of suitable pharmaceutically acceptable derivatives of a compound of Formula (I) include its sodium salt and potassium salt.
In another general aspect, there are provided pharmaceutical compositions comprising: (a) aztreonam or a pharmaceutically acceptable derivative thereof, and (b) a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof; wherein a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof is present in the composition in an amount from about 0.01 gram to about 8 gram per gram of aztreonam or a pharmaceutically acceptable derivative thereof.
Both, aztreonam and a compound of Formula (I) may be present in the composition in their free forms or in the form of their pharmaceutically acceptable derivatives (such as salts, pro-drugs, metabolites, esters, ethers, hydrates, polymorphs, solvates, complexes, or adducts). The specified ratio of aztreonam and compound of Formula (I) in the composition is calculated on the basis of their free forms. For example, if the composition comprises sodium salt of compound of Formula (I), the ratio of aztreonam to compound of Formula (I) is calculated using the equivalent amount of compound of Formula (I) present in the composition.
Individual amounts of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and aztreonam or a pharmaceutically acceptable derivative thereof in the composition may vary depending on clinical requirements. In some embodiments, a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof in the composition is present in an amount from about 0.01 gram to about 10 gram. In some other embodiments, aztreonam or a pharmaceutically acceptable derivative thereof in the composition is present in an amount from about 0.01 gram to about 10 gram.
In some embodiments, the pharmaceutical composition according to the invention comprises about 0.25 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 0.5 gram of aztreonam or a pharmaceutically acceptable derivative thereof. In some other embodiments, the pharmaceutical composition according to the invention comprises about 0.5 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 0.5 gram of aztreonam or a pharmaceutically acceptable derivative thereof.
In some embodiments, the pharmaceutical composition according to the invention comprises about 1 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 0.5 gram of aztreonam or a pharmaceutically acceptable derivative thereof.
In some embodiments, the pharmaceutical composition according to the invention comprises about 2 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 0.5 gram of aztreonam or a pharmaceutically acceptable derivative thereof.
In some other embodiments, the pharmaceutical composition according to the invention comprises about 0.25 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 1 gram of aztreonam or a pharmaceutically acceptable derivative thereof.
In some embodiments, the pharmaceutical composition according to the invention comprises about 0.5 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 1 gram of aztreonam or a pharmaceutically acceptable derivative thereof.
In some embodiments, the pharmaceutical composition according to the invention comprises about 1 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 1 gram of aztreonam or a pharmaceutically acceptable derivative thereof.
In some embodiments, the pharmaceutical composition according to the invention comprises about 2 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 1 gram of aztreonam or a pharmaceutically acceptable derivative thereof.
In some embodiments, the pharmaceutical composition according to the invention comprises about 4 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 1 gram of aztreonam or a pharmaceutically acceptable derivative thereof.
In some embodiments, the pharmaceutical composition according to the invention comprises about 2 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 2 gram of aztreonam or a pharmaceutically acceptable derivative thereof.
In some other embodiments, the pharmaceutical composition according to the invention comprises about 1 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 2 gram of aztreonam or a pharmaceutically acceptable derivative thereof.
The pharmaceutical compositions according to the invention may include one or more pharmaceutically acceptable carriers or excipients or the like. Typical, non-limiting examples of such carriers or excipients include mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, sodium crosscarmellose, glucose, gelatine, sucrose, magnesium carbonate, wetting agents, emulsifying agents, solubilizing agents, buffering agents, lubricants, preservatives, stabilizing agents, binding agents and the like. In some embodiments, the compositions according to present invention comprise arginine or a pharmaceutically acceptable salt thereof. The amount of arginine or a pharmaceutically acceptable salt thereof in the composition can vary widely depending on the requirement. In some embodiments, arginine or a pharmaceutically acceptable salt thereof is present in the composition in an amount of about 0.01 gram to about 5 gram of arginine or a pharmaceutically acceptable salt thereof per gram of aztreonam or a pharmaceutically acceptable salt thereof. In some other embodiments, arginine or a pharmaceutically acceptable salt thereof is present in the composition in an amount of about 0.01 gram to about 1 gram of arginine or a pharmaceutically acceptable salt thereof per gram of aztreonam or a pharmaceutically acceptable salt thereof.
The pharmaceutical compositions or the active ingredients according to the present invention may be formulated into a variety of dosage forms, such as solid, semi-solid, liquid and aerosol dosage forms. Typical, non-limiting examples of some dosage forms include tablets, capsules, powders, solutions, suspensions, suppositories, aerosols, granules, emulsions, syrups, elixirs and the like.
In some embodiments, pharmaceutical compositions according to the invention are in the form of a powder or a solution. In some other embodiments, pharmaceutical compositions according to the invention are present in the form of a powder or a solution that can be reconstituted by addition of a compatible reconstitution diluent prior to administration. In some other embodiments, pharmaceutical compositions according to the invention are in the form of a frozen composition that can be diluted with a compatible reconstitution diluent prior to administration. Typical, non-limiting example of suitable compatible reconstitution diluent includes water.
In some other embodiments, pharmaceutical compositions according to the invention are present in the form ready to use for parenteral administration.
The compositions according to the invention can be formulated into various dosage forms wherein the active ingredients and/or excipients may be present either together (e.g. as an admixture) or as separate components. When the various ingredients in the composition are formulated as a mixture, such compositions can be delivered by administering such a mixture to a subject using any suitable route of administration. Alternatively, pharmaceutical compositions according to the invention may also be formulated into a dosage form wherein one or more ingredients (such as active or inactive ingredients) are present as separate components. The composition or dosage form wherein the ingredients do not come as a mixture, but come as separate components, such composition/dosage form may be administered in several ways. In one possible way, the ingredients may be mixed in the desired proportions and the mixture is reconstituted in suitable reconstitution diluent and is then administered as required. Alternatively, the components or the ingredients (active or inert) may be separately administered (simultaneously or one after the other) in appropriate proportion so as to achieve the same or equivalent therapeutic level or effect as would have been achieved by administration of the equivalent mixture.
In some embodiments, pharmaceutical compositions according to the invention are formulated into a dosage form such that a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and aztreonam or a pharmaceutically acceptable derivative thereof, are present in the composition as admixture or as separate components. In some other embodiments, pharmaceutical compositions according to the invention are formulated into a dosage form such that a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and aztreonam or a pharmaceutically acceptable derivative thereof, are present in the composition as separate components.
In one general aspect, pharmaceutical compositions according to the invention are used in treatment or prevention of a bacterial infection.
In another general aspect, there are provided methods for treating or preventing a bacterial infection in a subject, said method comprising administering to said subject effective amount of a pharmaceutical composition according to the invention. In case of dosage forms wherein a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and aztreonam or a pharmaceutically acceptable derivative thereof, are present in the composition as separate components; a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof may be administered before, after or simultaneously with the administration of aztreonam or a pharmaceutically acceptable derivative thereof.
In yet another general aspect, there are provided methods for treating or preventing bacterial infections in a subject, said methods comprising administering to said subject an effective amount of: (a) aztreonam or a pharmaceutically acceptable derivative thereof, and (b) a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof: H2N
S03H
Formula (I)
In another general aspect, there are provided methods for treating or preventing bacterial infections in a subject, said methods comprising administering to said subject an effective amount of: (a) aztreonam or a pharmaceutically acceptable derivative thereof, and (b) a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof; wherein amount of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof administered is from about 0.01 gram to about 8 gram per gram of aztreonam or a pharmaceutically acceptable derivative thereof.
In some embodiments, there is provided a method for treating or preventing a bacterial infection in a subject, said method comprising administering to said subject: (a) aztreonam or a pharmaceutically acceptable derivative thereof, and (b) a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, in any of the following amounts:
(i) about 0.25 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 0.5 gram of aztreonam or a pharmaceutically acceptable derivative thereof;
(ii) about 0.5 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 0.5 gram of aztreonam or a pharmaceutically acceptable derivative thereof;
(iii) about 1 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 0.5 gram of aztreonam or a pharmaceutically acceptable derivative thereof;
(iv) about 2 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 0.5 gram of aztreonam or a pharmaceutically acceptable derivative thereof; (v) about 0.25 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 1 gram of aztreonam or a pharmaceutically acceptable derivative thereof;
(vi) about 0.5 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 1 gram of aztreonam or a pharmaceutically acceptable derivative thereof;
(vii) about 1 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 1 gram of aztreonam or a pharmaceutically acceptable derivative thereof;
(viii) about 2 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 1 gram of aztreonam or a pharmaceutically acceptable derivative thereof;
(ix) about 4 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 1 gram of aztreonam or a pharmaceutically acceptable derivative thereof;
(x) about 2 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 2 gram of aztreonam or a pharmaceutically acceptable derivative thereof; or
(xi) about 1 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 2 gram of aztreonam or a pharmaceutically acceptable derivative thereof.
In some embodiments, in the methods according to the invention, a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof is administered in an amount from about 0.01 gram to about 10 gram. In some other embodiments, in the methods according to the invention, aztreonam or a pharmaceutically acceptable derivative thereof is administered in an amount from about 0.01 gram to about 10 gram.
In some embodiments, in the methods according to the invention, a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof is administered before, after or simultaneously with the administration of aztreonam or a pharmaceutically acceptable derivative thereof. In the methods according to the invention, the pharmaceutical composition and/or other pharmaceutically active ingredients disclosed herein may be administered by any appropriate method, which serves to deliver the composition, or its constituents, or the active ingredients to the desired site. The method of administration can vary depending on various factors, such as for example, the components of the pharmaceutical composition and the nature of the active ingredients, the site of the potential or actual infection, the microorganism (e.g. bacteria) involved, severity of infection, age and physical condition of the subject. Some non-limiting examples of administering the composition to a subject according to this invention include oral, intravenous, topical, intrarespiratory, intraperitoneal, intramuscular, parenteral, sublingual, transdermal, intranasal, aerosol, intraocular, intratracheal, intrarectal, vaginal, gene gun, dermal patch, eye drop, ear drop or mouthwash. In some embodiments, the compositions or one or more active ingredients according to the invention are administered parenterally or orally.
In some embodiments, in the compositions and methods according to the invention, a compound of Formula (I) is "irans-sulfuric acid mono-{2-[5-(3-aminopropyl)-[l,3,4]oxadiazol-2- yl]-7-oxo-l,6-diaza-bicyclo[3.2.1]oct-6-yl} ester"; "(25,5i?)-2-(5-(3-aminopropyl)-l ,3,4- oxadiazol-2-yl-7-oxo-l ,6-diazabicyclo[3.2.1]octan-6-yl hydrogen sulphate"; "trans-6- (sulphooxy)-2-(5-(3-aminopropyl)-[l,3,4]-oxadiazol-2-yl)-7-oxo-l,6-diazabicyclo [3.2.1]-octane" or "sulfuric acid, mono [(li?,25,5i?)-2-[5-(3-aminopropyl)-l,3,4-oxadiazol-2-yl]-7-oxo-l ,6- diazabicyclo[3.2.1]oct-6-yl]ester or a stereoisomer thereof. In some embodiments, in compositions and methods according to the invention, a compound of Formula (I) a stereoisomer thereof is present as a sodium or potassium salt. In some other embodiments, there are provided compositions and methods comprising sodium or potassium salt of sulfuric acid, mono [(li?,25,5i?)-2-[5-(3-aminopropyl)-l ,3,4-oxadiazol-2-yl]-7-oxo-l,6-diazabicyclo[3.2.1]oct-6- yljester or a stereoisomer thereof.
In some embodiments, there is provided a method for increasing antibacterial effectiveness of aztreonam or a pharmaceutically acceptable derivative thereof in a subject, said method comprising co-administering aztreonam or a pharmaceutically acceptable derivative thereof, with a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof. In some other embodiments, there is provided a method for increasing antibacterial effectiveness of aztreonam or a pharmaceutically acceptable derivative thereof in a subject, said method comprising co-administering aztreonam or a pharmaceutically acceptable derivative thereof, with a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, wherein the amount of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof is from about 0.01 gram to about 8 gram per gram of aztreonam or a pharmaceutically acceptable derivative thereof.
A wide variety of bacterial infections can be treated or prevented using compositions and methods according to the invention. Typical, non -limiting examples of bacterial infections that can be treated or prevented using methods and/or pharmaceutical compositions according to the invention include E. coli infections, Yersinia pestis (pneumonic plague), staphylococcal infection, mycobacteria infection, bacterial pneumonia, Shigella dysentery, Serratia infections, Candida infections, Cryptococcal infection, anthrax, tuberculosis or infections caused by Pseudomonas aeruginosa, Acinetobacter baumannii or methicillin resistant Staphylococcus aurues (MRSA) etc.
The pharmaceutical compositions and methods according to the invention are useful in treatment or prevention of several infections, including for example, skin and soft tissue infections, febrile neutropenia, urinary tract infection, intraabdominal infections, respiratory tract infections, pneumonia (nosocomial), bacteremia meningitis, surgical infections and the like.
In some embodiments, pharmaceutical compositions and methods according to the invention are used in treatment or prevention of infections caused by resistant bacteria. In some other embodiments, the compositions and methods according to the invention are used in treatment or prevention of infections caused by bacteria producing one or more beta-lactamase enzymes.
In general, the pharmaceutical compositions and methods disclosed herein are also effective in preventing or treating infections caused by bacteria that are considered to be less or not susceptible to one or more of known antibacterial agents or their known compositions. Some non-limiting examples of such bacteria known to have developed resistance to various antibacterial agents include Acinetobacter, Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, Enterobacter, Klebsiella, Citrobacter and a like. In some other embodiments, there is provided a method for preventing or treating a bacterial infection in a subject, said infection is caused by bacteria producing carbapenem hydrolyzing beta-lactamase enzymes, said method comprising administering to said subject: (a) aztreonam or a pharmaceutically acceptable derivative thereof, and (b) compound of Formula (I) or stereoisomer or a pharmaceutically acceptable derivative thereof.
EXAMPLES
The following examples illustrate the embodiments of the invention that are presently best known. However, it is to be understood that the following are only exemplary or illustrative of the application of the principles of the present invention. Numerous modifications and alternative compositions, methods, and systems may be devised by those skilled in the art without departing from the spirit and scope of the present invention. The appended claims are intended to cover such modifications and arrangements. Thus, while the present invention has been described above with particularity, the following examples provide further detail in connection with what are presently deemed to be the most practical and preferred embodiments of the invention.
Example 1
The synergistic killing effect of the combinations according to invention was studied by performing time kill studies. In a typical time kill study, the freshly grown cultures were diluted to the required cell density (initial starting inoculum) in Cation adjusted Muller Hinton broth medium (BD, USA). The antibacterial agents (either alone or in combination) at the required concentrations were added into the culture-containing medium. The samples were incubated under shaking condition (120 rpm) at 37°C. Enumeration of viable bacterial count was done every 2 hour by diluting in normal saline and plating on to the Tryptic Soya Agar plates (BD, USA). The plates were incubated for 24 hours to arrive at the viable bacterial count. The results of these studies are summarized in Tables 1 and 2, wherein the antibacterial activity is expressed in terms of Logio CFU (Colony Forming Units) per ml. In general, the decrease of 1 Logio CFU/ml, corresponds to 90% killing of bacteria. Similarly, 2 Logio CFU/ml reductions indicates to 99% killing of bacteria and 3 Log CFU/ml reductions is equal to 99.9% killing of bacteria. Table 1 details the antibacterial activity of the combination according to invention against highly resistant K. pneumoniae NCTC 13443 strain producing NDM-1 , CMY Type, DHA-1/2, SHV, TEM beta-lactamase enzymes. The assay without any antibacterial agent was taken as control. As can be seen from the Table 1 , aztreonam (at 4 mcg/ml), imipenem (at 4 mcg/ml) and a compound of Formula (I) (at 4 mcg/ml) when used alone, were not effective in decreasing the bacterial count of K. pneumoniae NCTC 13443 throughout the duration of the study. However, surprisingly it has been observed that the combination of aztreonam and a compound of Formula (I) exhibited synergistic killing of the resistant strains of K. pneumonia NCTC 13443. The data reveals that combination of aztreonam (at 4 mcg/ml), and a compound of Formula (I) (at 4 mcg/ml) significantly reduced bacterial count throughout the duration of the study. More over, the combination according to the invention exhibited longer duration of action (maximum activity found at the end of 8 hours).
Figure imgf000021_0001
Table 2 details the antibacterial activity of the combination according to invention against highly resistant K. pneumoniae B88 strain producing NDM-1 , SHV, TEM and CTX-M Grl beta- lactamase enzymes. The assay without any antibacterial agent was taken as control. As can be seen from the Table 2, aztreonam (at 4 mcg/ml), imipenem (at 4 mcg/ml) and a compound of Formula (I) (at 4 mcg/ml) when used alone, were not effective in decreasing the bacterial count of K. pneumoniae B88 throughout the duration of the study. However, surprisingly it has been observed that the combination of aztreonam and a compound of Formula (I) exhibited synergistic killing of the resistant strains of K. pneumonia B88. The data reveals that combination of aztreonam (at 4 mcg/ml) and a compound of Formula (I) (at 4 mcg/ml) significantly reduced bacterial count over longer duration of times.
Figure imgf000022_0001
The results given in the Table 1 and Table 2, clearly and surprisingly demonstrate the potent antibacterial activity for the combination of aztreonam and a compound of Formula (I) against highly resistant strains of K. pneumoniae. Aztreonam and a compound of Formula (I) when used alone were found to be ineffective against these resistant bacterial strains. However, the combination of aztreonam and a compound of Formula (I) exhibited unusual and unexpected synergistic antibacterial effect for longer duration against highly resistant bacterial strains. Thus, a combination of aztreonam and a compound of Formula (I) has tremendous beneficial effect in inhibiting highly resistant bacterial strains demonstrating the noteworthy therapeutic advance in the treatment of infections caused by such pathogens.

Claims

1. A pharmaceutical composition comprising: (a) aztreonam or a pharmaceutically acceptable derivative thereof, and (b) a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof:
Figure imgf000023_0001
Formula (I)
2. A pharmaceutical composition according to Claim 1 , wherein a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof is present in the composition in an amount from about 0.01 gram to about 8 gram per gram of aztreonam or a pharmaceutically acceptable derivative thereof.
3. A pharmaceutical composition according to any one of Claims 1 or 2, wherein a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof is present in the composition in an amount from about 0.01 gram to about 10 gram.
4. A pharmaceutical composition according to any one of Claims 1 or 2, wherein aztreonam or a pharmaceutically acceptable derivative thereof is present in the composition in an amount from about 0.01 gram to about 10 gram.
5. A pharmaceutical composition according to any one of Claims 1 to 4, comprising: (a) aztreonam or a pharmaceutically acceptable derivative thereof, and (b) a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, in any of the following amounts: (i) about 0.25 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 0.5 gram of aztreonam or a pharmaceutically acceptable derivative thereof;
(ii) about 0.5 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 0.5 gram of aztreonam or a pharmaceutically acceptable derivative thereof;
(iii) about 1 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 0.5 gram of aztreonam or a pharmaceutically acceptable derivative thereof;
(iv) about 2 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 0.5 gram of aztreonam or a pharmaceutically acceptable derivative thereof;
(v) about 0.25 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 1 gram of aztreonam or a pharmaceutically acceptable derivative thereof;
(vi) about 0.5 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 1 gram of aztreonam or a pharmaceutically acceptable derivative thereof;
(vii) about 1 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 1 gram of aztreonam or a pharmaceutically acceptable derivative thereof;
(viii) about 2 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 1 gram of aztreonam or a pharmaceutically acceptable derivative thereof; (ix) about 4 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 1 gram of aztreonam or a pharmaceutically acceptable derivative thereof;
(x) about 2 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 2 gram of aztreonam or a pharmaceutically acceptable derivative thereof; or
(xi) about 1 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 2 gram of aztreonam or a pharmaceutically acceptable derivative thereof.
6. A pharmaceutical composition according to any one of Claims 1 to 5, wherein a compound of Formula (I) is irans-sulfuric acid mono-{2-[5-(3-aminopropyl)-[l,3,4]oxadiazol-2- yl]-7-oxo-l,6-diaza-bicyclo[3.2.1]oct-6-yl} ester or a stereoisomer thereof.
7. A pharmaceutical composition according to any one of Claims 1 to 5, wherein a compound of Formula (I) is (25,5i?)-2-(5-(3-aminopropyl)-l ,3,4-oxadiazol-2-yl-7-oxo-l ,6- diazabicyclo[3.2.1]octan-6-yl hydrogen sulphate or a stereoisomer thereof.
8. A pharmaceutical composition according to any one of Claims 1 to 5, wherein a compound of Formula (I) is ir ns-6-(sulphooxy)-2-(5-(3-aminopropyl)-[l,3,4]-oxadiazol-2-yl)-7- oxo-l,6-diazabicyclo[3.2.1]-octane or a stereoisomer thereof.
9. A pharmaceutical composition according to any one of Claims 1 to 5, wherein a compound of Formula (I) is sulfuric acid, mono [(li?,25,5i?)-2-[5-(3-aminopropyl)-l ,3,4- oxadiazol-2-yl]-7-oxo-l,6-diazabicyclo[3.2.1]oct-6-yl]ester or a stereoisomer thereof.
10. A pharmaceutical composition according to any one of Claims 1 to 5, wherein a compound of Formula (I) is present as a sodium or potassium salt of "sulfuric acid, mono [(li?,25,5i?)-2-[5-(3-aminopropyl)-l ,3,4-oxadiazol-2-yl]-7-oxo-l,6-diazabicyclo[3.2.1]oct-6- yl]ester or a stereoisomer thereof.
11. A pharmaceutical composition according to any one of Claims 1 to 10, wherein the composition is formulated into a dosage form such that a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and aztreonam or a pharmaceutically acceptable derivative thereof, are present in the composition as admixture or as a separate components.
12. A pharmaceutical composition according to Claim 11 , wherein the composition is formulated into a dosage form such that a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and aztreonam or a pharmaceutically acceptable derivative thereof, are present in the composition as separate components.
13. A pharmaceutical composition according to any one of the Claims 1 to 12, wherein the composition is in form of a powder or a solution.
14. A pharmaceutical composition according to Claim 13, wherein the composition is in the form of a powder or a solution that can be reconstituted by addition of a compatible reconstitution diluent for use in parenteral administration.
15. A pharmaceutical composition according to any one of Claims 1 to 14 for use in treatment or prevention of a bacterial infection.
16. A pharmaceutical composition according to Claim 12 for use in treatment or prevention of bacterial infection, wherein a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, is administered before, after or simultaneously with the administration of aztreonam or a pharmaceutically acceptable derivative thereof.
17. A method for preventing or treating a bacterial infection in a subject, said method comprising administering to said subject an effective amount of a pharmaceutical composition according to any one of Claims 1 to 14.
18. A method for treating or preventing a bacterial infection in a subject, said method comprising administering to said subject an effective amount a pharmaceutical composition according to Claim 12, wherein a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, is administered before, after or simultaneously with the administration of aztreonam or a pharmaceutically acceptable derivative thereof.
19. A method for treating or preventing a bacterial infection is a subject, said method comprising administering to said subject an effective amount of: (a) aztreonam or a pharmaceutically acceptable derivative thereof, and (b) a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof:
Figure imgf000027_0001
Formula (I)
20. A method according to Claim 19, wherein amount of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof administered is from about 0.01 gram to about 8 gram per gram of aztreonam or a pharmaceutically acceptable derivative thereof.
21. A method according to any one of Claims 19 or 20, wherein a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof is administered in an amount from about 0.01 gram to about 10 gram.
22. A method according to any of Claims 19 or 20, wherein aztreonam or a pharmaceutically acceptable derivative thereof is administered in an amount from about 0.01 gram to about 10 gram.
23. A method according to any of Claims 19 to 22, wherein aztreonam or a pharmaceutically acceptable derivative thereof, and a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, is administered in any of the following amounts: (i) about 0.25 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 0.5 gram of aztreonam or a pharmaceutically acceptable derivative thereof;
(ii) about 0.5 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 0.5 gram of aztreonam or a pharmaceutically acceptable derivative thereof;
(iii) about 1 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 0.5 gram of aztreonam or a pharmaceutically acceptable derivative thereof;
(iv) about 2 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 0.5 gram of aztreonam or a pharmaceutically acceptable derivative thereof;
(v) about 0.25 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 1 gram of aztreonam or a pharmaceutically acceptable derivative thereof;
(vi) about 0.5 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 1 gram of aztreonam or a pharmaceutically acceptable derivative thereof;
(vii) about 1 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 1 gram of aztreonam or a pharmaceutically acceptable derivative thereof;
(viii) about 2 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 1 gram of aztreonam or a pharmaceutically acceptable derivative thereof; (ix) about 4 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 1 gram of aztreonam or a pharmaceutically acceptable derivative thereof;
(x) about 2 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 2 gram of aztreonam or a pharmaceutically acceptable derivative thereof; or
(xi) about 1 gram of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, and about 2 gram of aztreonam or a pharmaceutically acceptable derivative thereof.
24. A method according to any one of Claims 19 to 23, wherein a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof, is administered before, after or simultaneously with the administration of aztreonam or a pharmaceutically acceptable derivative thereof.
25. A method according to any one of Claims 19 to 24, wherein a compound of Formula (I) is selected from the following:
(a) irans-sulfuric acid mono-{2-[5-(3-aminopropyl)-[l,3,4]oxadiazol-2-yl]-7-oxo-l ,6- diaza-bicyclo[3.2.1 ]oct-6-yl } ester;
(b) (25,5i?)-2-(5-(3-aminopropyl)-l,3,4-oxadiazol-2-yl-7-oxo-l,6-diazabicyclo[3.2.1] octan-6-yl hydrogen sulphate;
(c) ir ns-6-(sulphooxy)-2-(5-(3-aminopropyl)-[l,3,4]-oxadiazol-2-yl)-7-oxo-l,6- diazabicyclo[3.2.1]-octane;
(d) sulfuric acid, mono [(li?,25,5i?)-2-[5-(3-aminopropyl)-l,3,4-oxadiazol-2-yl]-7-oxo- 1 ,6-diazabicyclo[3.2.1 ]oct-6-yl]ester;
or a stereoisomer thereof.
26. A method according to any one of Claims 19 to 24, wherein a compound of Formula (I) is present as a sodium or potassium salt of sulfuric acid, mono [(li?,25,5i?)-2-[5-(3- aminopropyl)-l ,3,4-oxadiazol-2-yl]-7-oxo-l,6-diazabicyclo[3.2.1]oct-6-yl]ester or a stereoisomer thereof.
27. A method for increasing antibacterial effectiveness of aztreonam or a pharmaceutically acceptable derivative thereof in a subject, said method comprising coadministering aztreonam or a pharmaceutically acceptable derivative thereof, with a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof.
Figure imgf000030_0001
Formula (I)
28. A method according to Claim 27, wherein the amount of a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof is from about 0.01 gram to about 8 gram per gram of aztreonam or a pharmaceutically acceptable derivative thereof.
PCT/IB2015/052812 2014-04-18 2015-04-17 Pharmaceutical compositions comprising antibacterial agents WO2015159263A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1409/MUM/2014 2014-04-18
IN1409MU2014 2014-04-18

Publications (1)

Publication Number Publication Date
WO2015159263A1 true WO2015159263A1 (en) 2015-10-22

Family

ID=53298557

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2015/052812 WO2015159263A1 (en) 2014-04-18 2015-04-17 Pharmaceutical compositions comprising antibacterial agents

Country Status (1)

Country Link
WO (1) WO2015159263A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018193369A1 (en) * 2017-04-18 2018-10-25 Wockhardt Limited Antibacterial compositions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013149121A1 (en) * 2012-03-30 2013-10-03 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013149121A1 (en) * 2012-03-30 2013-10-03 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GOODMAN; GILMAN'S: "The Pharmacological Basis of Therapeutics", 1990, PERGAMON PRESS
S. M. BERGE ET AL., J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018193369A1 (en) * 2017-04-18 2018-10-25 Wockhardt Limited Antibacterial compositions

Similar Documents

Publication Publication Date Title
US10857138B2 (en) Pharmaceutical compositions comprising antibacterial agents
US20180243274A1 (en) Antibacterial compositions
WO2016151543A1 (en) Pharmaceutical compositions comprising antibacterial agents
US9789097B2 (en) Pharmaceutical compositions comprising antibacterial agents
AU2014338612C1 (en) Pharmaceutical compositions comprising antibacterial agents
EP3107539A1 (en) Pharmaceutical combinations comprising antibacterial agents
EP3116545A1 (en) Pharmaceutical compositions comprising antibacterial agents
AU2014338612A1 (en) Pharmaceutical compositions comprising antibacterial agents
EP3062793A1 (en) Pharmaceutical compositions comprising antibacterial agents
WO2015159263A1 (en) Pharmaceutical compositions comprising antibacterial agents
WO2015159167A1 (en) Pharmaceutical compositions comprising antibacterial agents
EP3125887A1 (en) Pharmaceutical compositions comprising cefepime or sulbactam
WO2018193368A1 (en) Antibacterial compositions
EP3060212A1 (en) Pharmaceutical compositions comprising sulbactam and imipenem

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15727457

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15727457

Country of ref document: EP

Kind code of ref document: A1